According to the American Cancer Society (“ACS”), lung cancer (both small cell and non-small cell) is the second most common cancer in both men and women (not counting skin cancer). About 14% of all new cancers are lung cancers and 85 % of those are non-small cell lung cancers (NSCLCs).
A New Option for NSCLC Patients
The US Food and Drug Administration (FDA) recently helped NSCLC patients fight this disease when the Agency approved Merck’s PD-1 inhibitor Keytruda® (pembrolizumab) as a first line treatment for metastatic NSCLC with high levels of PD-L1. The drug also was approved for NSCLC patients previously treated with a tumor proportion score of at least 1 %. The drug previously had been approved only as a second line treatment for this cancer.
Just one day after Merck’s approval, FDA approved Dako’s (a subsidiary of Agilent) companion diagnostic co-developed with Merck. The diagnostic identifies patients that are appropriate for Keytruda® therapy by determining PD-L1 expression status.
Clinical Adoption of Companion Diagnostics
Personalized medicine relies on accurate and reliable diagnostics to identify patients who will benefit from a therapy or treatment. The Merck/Dako partnership is yet another example of a successful partnership between drug and diagnostic developers. As reported by the Personalized Medicine Coalition, for the last three years, approximately 25% of all new drugs approved by FDA are personalized medicines that link a diagnostic and treatment. Thus, the Merck/Dako partnership and approval is yet another example of the trend toward the adoption of personalized medicine.
This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney.
This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary.
The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites.
In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.